par Hein, Matthieu ;Mungo, Anais ;Hubain, Philippe
Référence Revue médicale de Bruxelles, 40, 3, page (177-179)
Publication Publié, 2019-06-01
Article révisé par les pairs
Résumé : Vortioxetine is indicated for the treatment of moderate to severe major depressive episodes. The clinical action of Vortioxetine is mediated by selective blockade of serotonin reuptake and modulation of serotonin receptor activity. Although Vortioxetine appears to be more effective than placebo in the management of major depression, its place in the treatment of this pathology is unclear. Indeed, the lack of randomized controlled trials comparing Vortioxetine with first-line treatments for major depression (such as selective serotonin reuptake inhibitors) severely limits the interpretation of currently available data in the literature. However, given its potential pro-cognitive action, Vortioxetine may therefore be a treatment of choice in the management of cognitive symptoms associated with major depression, which justifies additional studies.